Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06415058 · ClinicalTrials.gov registry record
Study to Investigate Blood Samples Drawn With the HemoIV System
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- 19
- Enrollment target
NCT06415058: Clinical Trial study, sponsored by Vanderbilt University Medical Center.
NCT06415058 is a clinical trial that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06415058 was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- 19 participants
- Enrollment target
Study Summary
The goal of this study is to compare blood drawn using a device called HemoIV to standard-of-care blood drawn from a vein in the arm or from an IV catheter. The HemoIV is a device that is attached to an IV line. This device allows for blood to be drawn while a patient is receiving IV fluids. The main questions it aims to answer are: * Will the HemoIV device allow blood to be drawn without having to stop IV fluids? * Will the HemoIV device provide the same laboratory results as blood draws done by current standard practice? Participants will: * Receive standard medical procedures and/or treatment; * Have a HemoIV device inserted into their IV line in one arm; * Have an blood drawn twice from the HemoIV and from an IV line or needle stick from a vein in the other arm. The second blood draw will be done about 8-22 hours after the first blood draw; * Have the device removed after the second blood draw; * Receive a phone call about 8 days later to see how you are doing.
Primary Outcome
White Blood Cell Count (WBC) Min: 3.9 to Max:10.7 (10 to the power of 3/uL)
Interventions
- DEVICE HemoIV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2024-05-02 |
| Est. Completion | 2025-02-21 |
Why NCT06415058 stopped before completion
NCT06415058 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which HemoIV is the first listed.
NCT06415058 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06415058 about?
NCT06415058 is a clinical study titled "Study to Investigate Blood Samples Drawn With the HemoIV System". The goal of this study is to compare blood drawn using a device called HemoIV to standard-of-care blood drawn from a vein in the arm or from an IV catheter. The HemoIV is a device that is attached to an IV line. This device allows for blood to be drawn while a patient is receiving IV fluids. The ma...
What is the current status of trial NCT06415058?
This trial is currently terminated. The enrollment target is 19 participants. The study started on 2024-05-02. Estimated completion is 2025-02-21.
What interventions are being tested in trial NCT06415058?
The interventions under investigation include: HemoIV (DEVICE).
Who is sponsoring clinical trial NCT06415058?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI